Association of intradialytic hypertension and antihypertensive medication use in patients undergoing maintenance hemodialysis: a prospective observational study

Mariam Sherif; Seeba Zachariah; Rajaram Jagdale

doi:10.12688/f1000research.144153.2

Home Browse Association of intradialytic hypertension and antihypertensive medication...

ALL Metrics

Views

Downloads

Get PDF

Get XML

Export

▬

✚

Research Article

Revised

Association of intradialytic hypertension and antihypertensive medication use in patients undergoing maintenance hemodialysis: a prospective observational study

[version 2; peer review: 1 approved with reservations, 1 not approved]

Mariam Sherif¹, Seeba Zachariah ¹, Rajaram Jagdale^2,3

PUBLISHED 06 Jan 2025

Author details Author details

¹ College of Pharmacy, Gulf Medical University, Al Jurf, Ajman, 4184, United Arab Emirates
² College of Medicine, Gulf Medical University, Al Jurf, Ajman, 4184, United Arab Emirates
³ Department of Nephrology, Thumbay University Hospital, Al jurf, Ajman, 4184, United Arab Emirates

Mariam Sherif
Roles: Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Software, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing

Seeba Zachariah
Roles: Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Software, Supervision, Validation, Writing – Original Draft Preparation, Writing – Review & Editing

Rajaram Jagdale
Roles: Conceptualization, Writing – Review & Editing

OPEN PEER REVIEW

REVIEWER STATUS

Abstract

Background

In patients with end-stage kidney disease (ESKD) undergoing maintenance hemodialysis, intradialytic hypertension and intradialytic hypotension are the common complications. The study aimed to collect and assess intradialytic Blood Pressure (BP) complications and their association with BP medications.

Methods

This was a prospective observational study, conducted at the hemodialysis center in a teaching hospital in the UAE, that provide a specialist’s care for the patients receiving ongoing hemodialysis. Patient demographics, medications used, lab data and the peridialytic BP (pre-, intra-, and post-) dialytic BP were collected for a period of 6 months. SPSS Version 29, Armonk, NY was used for statistical analysis. Pearson Chi-square test and Fischer’s Exact test were used to compare the association between categorical variables to intradialytic hypertension and hypotension. Binary logistic regression was used to find the effect of predictive variables to the presence or absence of intradialytic complications.

Results

Blood pressure data was collected from 47 hemodialysis patients for a total of 2616 hemodialysis sessions during the 6 months study period. Non-dialysable antihypertensives were predominantly used. Beta-blockers (68%) and calcium channel blockers (66%) were the commonly used drug classes. Intradialytic hypertension events were diagnosed in 49 (1.9%) hemodialysis sessions and intradialytic hypotension was diagnosed in 23 (0.9%) hemodialysis sessions. Chi-square test showed association of antihypertensive medication use to the occurrence of intradialytic hypertension; especially ARBs, and alpha-1 blockers. Beta-blockers and calcium channel blockers use were associated with decreased number of intradialytic hypertension events (p-value <0.05). Regression showed broad confidence intervals. On the other hand, antihypertensive medication use showed no association with intradialytic hypotension.

Conclusions

Even though antihypertensive medications showed varying occurance of intradialytic hypertension, the results are inconclusive due to large confidence intervals that could be due to the presence of colliniarity between the variables. Future studies are required in larger populations.

Keywords

Hypertension, comorbidities, intradialytic hypertension, intradialytic hypotension, factors, dialysis patients

Corresponding author: Seeba Zachariah

Competing interests: No competing interests were disclosed.

Grant information: The author(s) declared that no grants were involved in supporting this work.

Copyright: © 2025 Sherif M et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite: Sherif M, Zachariah S and Jagdale R. Association of intradialytic hypertension and antihypertensive medication use in patients undergoing maintenance hemodialysis: a prospective observational study [version 2; peer review: 1 approved with reservations, 1 not approved]. F1000Research 2025, 13:634 (https://doi.org/10.12688/f1000research.144153.2) First published: 14 Jun 2024, 13:634 (https://doi.org/10.12688/f1000research.144153.1) Latest published: 06 Jan 2025, 13:634 (https://doi.org/10.12688/f1000research.144153.2)

Revised Amendments from Version 1

Following are the changes made in version 2.
No changes in the title, and authors.
The abstract is modified to include the regression analysis and its results.
The introduction is rephrased to increase clarity. Two references are replaced.
The method is modified by adding more details about the study setting and data collection procedure. Also, binary logistic regression is used to find the odds ratio and 95% confidence interval.
In the results, the new results from binary regression are added as a new table, and elaborated the results.
Reorganized the discussion part.
The conclusion is modified including the results from binary regression.

See the authors' detailed response to the review by Carmine Zoccali
See the authors' detailed response to the review by Peter K Uduagbamen

Introduction

Although hypertension is prevalent in more than 80% of chronic maintenance hemodialysis patients, there is no consensus about the BP threshold, BP target, and the effect of BP reduction on cardiovascular outcomes. Hypertension in the hemodialysis population is multifactorial and is different from other patient populations.¹^–⁵ Patients undergoing hemodialysis may experience several complications in their treatment journey that affect their quality of life. Many patients have varying adherence to therapy and struggle to achieve optimal blood pressure outcomes.⁶^–¹⁰

Although the drug treatment is effective, the number of patients who achieved adequate BP control is limited. BP obtained in dialysis centers poorly represents the actual blood pressure status of the hemodialysis patients, makes the management of hypertension particularly challenging. Despite calculating the fluid removal during hemodialysis, many patients experience intradialytic BP complications.¹¹^–¹³ Intradialytic hypertension (IDHTN) and hypotension (IDH) are common complications during hemodialysis. Their prevalence range 20.2–33.4% and 10-12% respectively. These complications occur due to multiple factors including volume overload, endothelial dysfunction, electrolyte alterations, and/or overactive sympathetic nervous system and renin angiotensin aldosterone system (RAAS). These BP complications are associated with increased risk of mortality.¹⁴^,¹⁵

Beta-blockers, (dihydropyridine) calcium channel blockers, and renin-angiotensin system (RAS) inhibitors are commonly used in the hemodialysis patients followed by central α agonists, peripheral α antagonists, and direct vasodilators, and diuretics. The choice of antihypertensives depends on factors including comorbidity, residual renal function, dialyzability, and cardiovascular benefits. Compared to dialyzable beta blockers, nondialyzable beta blockers are associated with reduced frequency of intradialytic hypertension. A single center study showed that intradialytic hypertension is high with highly dialysable antihypertensive use. CCB use is associated with a lower risk of hypotension during dialysis, independent of predialysis systolic BP and other antihypertensives use. ACE inhibitors or ARBs, and diuretics had increased risk of hemodialysis hypotension compared with CCBs, β and α–β blockers.¹¹^–¹⁹

Aim

The aim of the study was to investigate the association of intradialytic hyper or hypotension and the antihypertensive medications use in patients undergoing dialysis.

Methods

Research design & setting

This prospective observational study was conducted in the hemodialysis unit of a 350 bedded tertiary care teaching hospital in the UAE. This is one of the largest hemodialysis units among the private sector hospitals in the UAE. The center had dialysis sessions starting from 7 AM to 11 PM and was working in 3 shifts (morning, noon and evening). Most patients were on weekly 3 times dialysis sessions. The center was functioning under the supervision of a nephrologist. For the research, patient information was mostly collected from electronic medical records and the physician’s register of patient’s medications. The data collection process began on November 1, 2022, and continued until the end of April 2023.

Study population

Fifty-six patients with end-stage kidney disease and hypertension and were undergoing regular maintenance hemodialysis at the study site. After removing patients who had been on dialysis for less than three months, the total number of participants was 47.

Ethical concerns

Patient confidentiality was maintained, and consent was obtained from the patients for the study. Ethical approval for the study was granted by the institutional review board of Gulf Medical University (IRB approval date: 19 November 2020; Ref No. IRB/COP/STD/07/Nov-2020). The principles of the Declaration of Helsinki were used in this research.

Data collection

All the data were collected using a standard data collection from the electronic medical records and the dialysis register maintained by the dialysis unit staff. Ambulatory or home BP measurements were not feasible and were not used in the study. For every patient, a trained dialysis nurse measured and recorded BP at the start of dialysis (Pre dialysis BP), BP during dialysis (measured and recorded every 30 minutes, using the automatic cuff attached to the HD machine, an average of 6-8 BP reading is taken by the researcher (intra dialytic BP) and BP after the dialysis session ends (post dialytic BP). Generally, each hemodialysis session was for 4 hours unless complications led to an early finish. Data collection continued for six months to identify the patterns of blood pressure, as well as complications of intradialytic hypertension, and hypotension that occurred during each dialysis session. All patients had same type dialyzer and dialysate solution and none were on low sodium dialysate. The events of IDHTN and IDH were based on the clinicians’ diagnosis of the same which was based on the patient’s symptoms.

Data analysis

Descriptive statistics was used to summarize the data. Pearson Chi-square test and Fischer’s Exact test were used to compare the association between categorical variables to intradialytic hypertension and hypotension. Whereever association was found significant, Mantel-Haenszel test and b inary logistic regression was used to estimate the odds ratios. SPSS Version 29, Armonk, NY (https://www.ibm.com/support/pages/downloading-ibm-spss-statistics-29011) was used for statistical analysis.

Results

A total of 2616 hemodialysis sessions occurred during the 6 months period for 47 maintenance hemodialysis patients. Patients were of age 55 (±13) years. 55.3% of patients were less than 60 years old and 74.5% of patients were males. Health insurance was present for 85% patients. Three times per week dialysis was for 62% patients. An overview of the sociodemographic and health status characteristics of the 47 study participants is given in Table 1.³⁰

Table 1. Patient demographics at baseline.

Characteristics	Mean (±SD) or n (%)
Age in years, Mean (±SD)	55 (±13)
Less than 60 years, n (%)	26 (55.3%)
60 years or above, n (%)	21 (44.7%)
Gender
Male	35 (74.5%)
Female	12 (25.5%)
Ethnicity
Arab	21 (44.7%)
Non-Arab	26 (55.4%)
Marital status
Married	42 (89.4%)
Not married	5 (10.6%)
Employment status: Employed	27 (57.4%)
Health insurance active	40 (85.1%)
Smoking status:
Current smoker	1 (2.1%)
Ex-smoker	04 (8.5%)
Never smoker	42 (89.3%)
BMI in kg/m², Mean (±SD)	28.12 (±5.77)
Dialysis vintage in months, mean (±SD)	26.89 (16.74)
Number of dialysis sessions per week
Two times per week	18 (38)
Three times per week	29 (62)
Comorbidities
Diabetes	27 (57.4)
Hypertension	40 (85.1)
Dyslipidemia	9 (19.1)
Cerebrovascular accident (CVA)	14 (29.8)
Ischemic heart disease	6 (12.8)
Anemia	27 (57.4)
Asthma	1 (2.1)
Depression	1 (2.1)
Obstructive sleep apnea (OSA)	1 (2.1)

Average institutional blood pressure recordings before, during, and after dialysis of the study population were provided in Table 2. Elevated SBP was more commonly seen compared to elevated DBP in the pre-, intra- and post dialysis periods.

Table 2. Average peri-dialytic values of 6 months study period (n=47).

Blood pressure	Mean	(±SD)
Pre dialytic SBP (mmHg)	153.6	14.5
Pre dialytic DBP (mmHg)	82.1	9.3
Intra dialytic SBP (mmHg)	149.6	14.7
Intra dialytic DBP (mmHg)	81.2	7.1
Post dialytic SBP (mmHg)	149.2	17.1
Post dialytic DBP (mmHg)	81.0	7.6
Pre dialytic weight (kg)	77.2	16.8
Post dialytic weight (kg)	74.8	16.4
Ultrafiltration (L)	2.4	0.7

Calcium channel blockers and beta blockers were the commonly used antihypertensive medications ( Figure 1). Non dialyzable antihypertensives were mostly used. Amlodipine (61.7%), bisoprolol (44.7%), furosemide (20%), doxazosin (29.8%), moxonidine (21.3%), hydralazine (12.8%), nebivolol (10.6%), and carvedilol (8.5%) were the commonly used ones. Other antihypertensive use was less than 25%. A combination of four or more antihypertensives was used by 16 (34%) patients, indicating the presence of resistant hypertension.

Figure 1. Antihypertensive use among the study population (n=47).

X-axis shows percentage of patients on antihypertensives, and Y-axis shows antihypertensive drug class.

Out of the 2616 hemodialysis sessions, 49 (1.9%) sessions had intradialytic hypertension and 23 (0.9%) dialysis sessions had intradialytic hypotension. This include intradialytic hypertension in 16 (34%) patients and Intradialytic hypotension in 11(23%). Both events occurred in 3 (6%) patients. Twenty-three (49%) patients had no interdialytic BP complications.

Association between antihypertensive medication and IDHTN is provided in Table 3. The association was statistically significant for Angiotensin Receptor Blocker (ARB), Beta Blockers, Calcium Channel Blockers, Alpha-1 Blockers and diuretics. Centrally acting drugs and vasodilators did not show statistically significant association to IDHTN.

Table 3. Association of antihypertensives to intradialytic Blood Pressure Complications.

Antihypertensive class	Antihypertensive use	No Intra-dialytic Hypertension	Intra-dialytic Hypertension	P-value^#
Angiotensin Receptor Blocker (ARB)	Nonuser	27 (57.4%)	9 (19.1%)	0.02*
Angiotensin Receptor Blocker (ARB)	User	4 (8.5%)	7 (14.9%)	0.02*
Beta Blockers	Nonuser	15 (31.9%)	2 (4.3%)	0.02*
Beta Blockers	User	16 (34.0%)	14 (29.8%)	0.02*
Calcium Channel Blockers	Nonuser	13 (27.7%)	1 (2.1%)	0.01*
Calcium Channel Blockers	User	18 (38.3%)	15 (31.9%)	0.01*
Alpha-1 Blockers	Nonuser	24 (51.1%)	7 (14.9%)	0.02*
Alpha-1 Blockers	User	7 (14.9%)	9 (19.1%)	0.02*
Diuretics	Nonuser	21 (44.7%)	5 (10.6%)	0.02*
Diuretics	User	10 (21.3%)	11 (23.4%)	0.02*
Central acting agents	Nonuser	26 (55.3%)	10 (21.3%)	0.10
Central acting agents	User	5 (10.6%)	6 (12.8%)	0.10
Vasodilators	Nonuser	28 (59.6%)	13 (27.7%)	0.38
Vasodilators	User	3 (6.4%)	3 (6.4%)	0.38

* P value <0.05.

# Pearson Chi-Square test or Fischer exact test.

Age (<60 years or more), gender (male or female), ethnicity (Arab or Non-Arab), frequency of dialysis per week (twice or thrice), polypharmacy (≥5 medications), Hemoglobin level (moderate-severe anemia), and presence of comorbidities diabetes or hypertension did not show any association to IDHTN. Dialysis vintage (>1year vs < 1year), resistant hypertension with the use of 4 or more antihypertensive drugs, showed association to IDHTN.

None of the antihypertensive drug classes showed association to intradialytic hypotension.

Patients using ARBs or alpha-1 blockers had higher intradialytic hypertension events. Beta-blocker and calcium channel users had lower intradialytic hypertension. Other antihypertensive use did not show any association with intradialytic hypertension. Antihypertensive medication use showed no association with intradialytic hypotension.

A binary logistic regression analysis was performed to examine the relation between antihypertensive use and IDHTN. Results are shown in the Table 4.

Table 4. Effect of Antihypertensives on incidence of Intradialytic hypertension.

Variable	Category	No IDHTN (n=31)	IDHTN (n=16)	Odds ratio (OR)	P value	95% Confidence interval
Variable	Category	No IDHTN (n=31)	IDHTN (n=16)	Odds ratio (OR)	P value	Lower	Upper
ARB	Nonuser	27	9	5.25	.024	1.24	22.19
ARB	User	4	7	5.25	.024	1.24	22.19
BB	Nonuser	15	2	6.56	.025	1.27	33.85
BB	User	16	14	6.56	.025	1.27	33.85
CCB	Nonuser	13	1	10.83	.030	1.27	92.66
CCB	User	18	15	10.83	.030	1.27	92.66
A1B	Nonuser	24	7	4.41	.025	1.20	16.14
A1B	User	7	9	4.41	.025	1.20	16.14
Diuretic	Nonuser	21	5	4.62	.021	1.26	16.92
Diuretic	User	10	11	4.62	.021	1.26	16.92
Resistant HTN	No	25	6	6.94	.005	1.80	26.75
Resistant HTN	Yes	6	10	6.94	.005	1.80	26.75
Dialysis vintage >1 year	No	8	9	0.27	.044	0.08	0.97
Dialysis vintage >1 year	Yes	23	7	0.27	.044	0.08	0.97

The crude odds ratio indicated a statistically significant association. However, the adjusted multinomial regression analysis showed no significant odds ratios. It could be due to the multiple instances of collinearity among the variables that was revealed in the correlation analysis.

Discussion

Hemodialysis helps manage hypertension in patients with end-stage kidney disease (ESKD) alongside the use of antihypertensive medications. The association between antihypertensive use and intradialytic blood pressure complications was a new study from the Middle East region. Thrice-weekly sessions are the most common approach for maintenance hemodialysis. Frequent dialysis sessions are crucial for effectively removing waste products and excess fluid from the body, helping to maintain overall stability in ESKD patients. Antihypertensive medications are essential for controlling blood pressure in dialysis patients, as hypertension is a common comorbidity in this population and is linked to increased cardiovascular risks. Effective fluid removal is critical to prevent complications associated with fluid overload, such as congestive heart failure and pulmonary edema in ESKD. Some antihypertensive medications were more likely to be associated with intradialytic hypertension than others.¹¹^–¹⁵

Hemodialysis helps in managing hypertension in ESKD patients along with antihypertensive medications. The antihypertensive use and its association with intradialytic BP complications was novel finding from the Middle East region. Some antihypertensive medications were associated with intradialytic hypertension compared to others. Thrice-weekly sessions were the most common approach for maintenance hemodialysis. Frequent dialysis sessions are crucial for effectively removing waste products and excess fluid from the body to maintain proper kidney function. Antihypertensive medications are essential for controlling blood pressure in dialysis patients, as hypertension is a common comorbidity in this population and is associated with increased cardiovascular risks. Effective fluid removal is critical to prevent complications associated with fluid overload, such as congestive heart failure and pulmonary edema in ESKD.²⁰^,²¹

The most common intradialytic complication in our study was IDHTN experienced by 34% of patients and accounted for 1.9% of total dialysis sessions. IDH occurred in 23% patients and accounted for 0.9% of total dialysis sessions. Age, gender, ethnicity, dialysis frequency, and polypharmacy did not show any association to IDHTN. Dialysis wintage less than 1 year and use of 4 or more antihypertensive drugs were found to increase the risk of IDHTN.

Beta-blockers were the most frequently prescribed cardiovascular medications among dialysis patients in this study. These agents are well-established for their efficacy in lowering heart rate and blood pressure, making them essential in managing hypertension and reducing cardiac workload. Loop diuretics, such as furosemide, play a critical role in managing fluid overload and congestive heart failure, common complications in dialysis patients resulting from impaired renal function. These agents facilitate diuresis and contribute to maintaining fluid balance and hemodynamic stability in this high-risk population. Furthermore, beta-blockers have demonstrated benefits in improving cardiovascular outcomes and reducing mortality in patients with chronic kidney disease (CKD) and end-stage kidney disease (ESKD). Their use in this population is consistent with current clinical guidelines and reflects a proactive approach to mitigating cardiovascular risk.²²^–²⁴

In this study population, both beta-blockers and calcium channel blockers (CCBs) were associated with a higher incidence of intradialytic hypertension. CCBs are also effective in lowering blood pressure and have been shown to improve outcomes in CKD, particularly by slowing the progression of renal disease. Due to their favorable safety profile and tolerability in patients with compromised kidney function, CCBs are considered an appropriate therapeutic option for dialysis patients, many of whom present with pre-existing cardiovascular conditions.²²^–²⁴

Beta-blockers were the most commonly prescribed cardiovascular medication among dialysis patients. Beta-blockers are well-known for their ability to lower heart rate and blood pressure, making them valuable in managing hypertension and reducing the workload on the heart. Additionally, they have been shown to be beneficial in improving overall cardiovascular outcomes and reducing mortality rates in patients with CKD and ESKD. The use of beta-blockers in this population aligns with current guidelines and represents a proactive approach to cardiovascular risk reduction. Beta-blockers calcium channel blockers (CCBs) were associated with more frequent intradialytic hypertension in our study population. CCBs are also effective in reducing blood pressure and have been shown to improve outcomes in CKD patients, particularly in terms of slowing the progression of kidney disease. CCBs are considered safe and well-tolerated in patients with impaired kidney function, making them a suitable choice for dialysis patients who often have pre-existing cardiovascular complications. Loop diuretics, such as furosemide, are crucial for managing fluid overload and congestive heart failure, common complications in dialysis patients due to impaired kidney function. These medications promote diuresis and help maintain fluid balance and hemodynamic stability in this vulnerable population.¹⁴^,²²^,²³

The low utilization of ACE inhibitors in this study may be attributed to individual patient characteristics, contraindications, or specific preferences of healthcare providers. Similarly, thiazide diuretics are often used as add-on therapy to manage hypertension in CKD patients. Thiazide diuretics are effective in promoting diuresis and blood pressure control, but their usage may be limited in patients with advanced kidney disease due to decreased renal excretion and potential electrolyte disturbances. Vasodilators, such as hydralazine and Nifedipine, were also relatively underutilized. Vasodilators act to relax blood vessels, thus reducing blood pressure and improving cardiac function. Their low usage in this study could be attributed to various factors, including the presence of alternative medications or individual patient responses.¹³^,¹⁵^,²²^,²⁴

Hypertension is a significant concern among dialysis patients due to impaired kidney function and fluid balance. Our study observed that a substantial proportion of patients were prescribed antihypertensive medications. Intradialytic BP complications are reported in many studies, but not their association with antihypertensive medications, making our study unique. Intradialytic hypertension is a concern that needs to be addressed more effectively.²⁵^–³⁰

Conclusion

Intradialytic hypertension was the most common BP complication among our study population, contrary to the common belief that intradialytic hypotension is the most common complication among patients undergoing hemodialysis. Beta-blockers and calcium channel blockers were the most prescribed antihypertensives in the study population. Patients using ARBs or alpha-1 blockers had higher intradialytic hypertension events. Beta-blocker and calcium channel users had lower intradialytic hypertension events. Other antihypertensive were not showing a significant difference. Regression analysis showed wide confidence intervals for all such relationships demanding further research.

Strengths and limitations

The study was conducted in one of the biggest private healthcare settings in the United Arab Emirates. Most of the patients were on antihypertensive medications for their hypertension management. This study focused on assessing relationship of antihypertensive medication on intradialytic blood pressure complications and the study being conducted in a single site produces a cohort effect as all patients receive same standard of care during the study period.

Though number of study population was limited, it was enough to find statistically significant association. Medication adherence was not collected in detail in this study. Patients were asked about medication adherence and found they were generally adherent to their antihypertensive medications, as there were clinical pharmacy interventions prior to this study to improve medication adherence. Reinforcement advice was provided to the study participants on the importance of medication adherence.

Data availability

Figshare: BP in Hemodialysis patients.xlsx. https://doi.org/10.6084/m9.figshare.24417031.v2.³⁰

Data are available under the terms of the Creative Commons Attribution 4.0 International license (CC-BY 4.0).

References

1. Webster AC, Nagler EV, Morton RL, et al.: Chronic Kidney Disease. Lancet. 2017; 389(10075): 1238–1252. Publisher Full Text
2. Thurlow JS, Joshi M, Yan G, et al.: Global Epidemiology of End-Stage Kidney Disease and Disparities in Kidney Replacement Therapy. Am. J. Nephrol. 2021; 52(2): 98–107. PubMed Abstract | Publisher Full Text | Free Full Text
3. Al-Shamsi S, Regmi D, Govender RD: Chronic kidney disease in patients at high risk of cardiovascular disease in the United Arab Emirates: A population-based study. PLoS One. 2018; 13(6): e0199920. PubMed Abstract | Publisher Full Text | Free Full Text
4. Richards N, Hassan MH, Saleh AK, et al.: Epidemiology and referral patterns of patients with chronic kidney disease in the Emirate of Abu Dhabi. Saudi J. Kidney Dis. Transpl. 2015; 26(5): 1028–1034. PubMed Abstract | Publisher Full Text
5. O’Lone E, Viecelli AK, Craig JC, et al.: Cardiovascular Outcomes Reported in Hemodialysis Trials. J. Am. Coll. Cardiol. 2018; 71(24): 2802–2810. Publisher Full Text
6. Alzahrani AMA, al-Khattabi GH: Factors Influencing Adherence to Hemodialysis Sessions among Patients with End-Stage Renal Disease in Makkah City. Saudi J. Kidney Dis. Transpl. 2021; 32(3): 763–773. PubMed Abstract | Publisher Full Text
7. Sarafidis PA, Persu A, Agarwal R, et al.: Hypertension in dialysis patients: A consensus document by the European Renal and Cardiovascular Medicine (EURECA-M) working group of the European Renal Association–European Dialysis and Transplant Association (ERA-EDTA) and the hypertension and the Kidney Working Group of the European Society of Hypertension (ESH). Nephrol. Dial. Transplant. 2017; 32(4): 620–640. Publisher Full Text
8. Thomas D, Joseph J, Francis B, et al.: Effect of patient counseling on quality of life of hemodialysis patients in India. Pharm. Pract. 2009; 7(3): 181–184. PubMed Abstract | Publisher Full Text | Free Full Text
9. Kelly JT, Su G, Zhang L, et al.: Modifiable lifestyle factors for primary prevention of CKD: a systematic review and meta-analysis. J. Am. Soc. Nephrol. 2021; 32(1): 239–253. PubMed Abstract | Publisher Full Text | Free Full Text
10. Canaud B, Van der Sande F, Kooman J: Predialysis hyponatremia and positive change of natremia within hemodialysis sessions are strong indicators of poor cardiovascular outcome in hemodialysis patients. Kidney Int. Rep. 2021; 6(2): 248–251. PubMed Abstract | Publisher Full Text | Free Full Text
11. Agarwal R: Blood pressure and mortality among hemodialysis patients. Hypertension. 2010 Mar 1; 55(3): 762–768. PubMed Abstract | Publisher Full Text | Free Full Text
12. Burnier M, Damianaki A: Hypertension as cardiovascular risk factor in chronic kidney disease. Circ. Res. 2023 Apr 14; 132(8): 1050–1063. Publisher Full Text
13. Ahmed A, Jorna T, Bhandari S: Should we STOP angiotensin-converting enzyme inhibitors/angiotensin receptor blockers in advanced kidney disease? Nephron. 2016 Jun 24; 133(3): 147–158. PubMed Abstract | Publisher Full Text
14. Adejumo OA, Edeki IR, Oyedepo DS, et al.: The prevalence and risk of mortality associated with intradialytic hypertension among patients with end-stage kidney disease on haemodialysis: A systematic review and meta-analysis. PLoS One. 2024 Jun 11; 19(6): e0304633. PubMed Abstract | Publisher Full Text | Free Full Text
15. Tokareva A, Borovkova N, Polyakova I: High dialysis clearance of drugs predicts intradialytic hypertension in hemodialysis patients. Eur. Heart J. 2020 Nov 1; 41(Supplement_2): ehaa946.3325. Publisher Full Text
16. Bakris GL, Burkart JM, Weinhandl ED, et al.: Intensive Hemodialysis, Blood Pressure, and Antihypertensive Medication Use. Am. J. Kidney Dis. 2016 Nov 1; 68(5, Supplement 1): S15–S23. PubMed Abstract | Publisher Full Text Reference Source
17. Lefranc Torres A, Correa S, Mc Causland FR: Association of Calcium Channel Blocker Use With Intradialytic Hypotension in Maintenance Hemodialysis. Kidney Int. Rep. 2024 Mar 27; 9(6): 1758–1764. Publisher Full Text | PubMed Abstract | Free Full Text
18. Maruyama T, Takashima H, Abe M: Blood pressure targets and pharmacotherapy for hypertensive patients on hemodialysis. Expert Opin. Pharmacother. 2020 Jul 2; 21(10): 1219–1240. Publisher Full Text
19. Prasad B, Hemmett J, Suri R: Five Things to Know About Intradialytic Hypertension. Can. J. Kidney Health Dis. 2022 Jun 21; 9. PubMed Abstract | Publisher Full Text | Free Full Text
20. Canaud B, Chazot C, Koomans J, et al.: Fluid and hemodynamic management in hemodialysis patients: challenges and opportunities. J. Bras. Nefrol. 2019 October 24; 41: 550–559. PubMed Abstract | Publisher Full Text | Free Full Text
21. Flythe JE, Chang TI, Gallagher MP, et al.: Blood pressure and volume management in dialysis: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2020; 97(5): 861–876. PubMed Abstract | Publisher Full Text | Free Full Text
22. Fu EL, Clase CM, Evans M, et al.: Comparative Effectiveness of Renin-Angiotensin System Inhibitors and Calcium Channel Blockers in Individuals with Advanced CKD: A Nationwide Observational Cohort Study. Am. J. Kidney Dis. 2021; 77(5): 719–729.e1. PubMed Abstract | Publisher Full Text
23. Mujtaba F, Qureshi R, Dhrolia M, et al.: Frequency of Intradialytic Hypertension Using Kidney Disease: Improving Global Outcomes (KDIGO) Suggested Definition in a Single Hemodialysis Centre in Pakistan. Cureus. 2022 Dec 29; 14(12): e33104. PubMed Abstract | Publisher Full Text | Free Full Text
24. Hundemer GL, Knoll GA, Petrcich W, et al.: Kidney, Cardiac, and Safety Outcomes Associated with α-Blockers in Patients with CKD: A Population-Based Cohort Study. Am. J. Kidney Dis. 2021; 77(2): 178–189.e1. PubMed Abstract | Publisher Full Text
25. Inrig JK: Intradialytic hypertension: a less-recognized cardiovascular complication of hemodialysis. Am. J. Kidney Dis. 2010; 55(3): 580–589. PubMed Abstract | Publisher Full Text | Free Full Text
26. Locatelli F, Cavalli A, Tucci B: The growing problem of intradialytic hypertension. Nat. Rev. Nephrol. 2010 Jan; 6(1): 41–48. PubMed Abstract | Publisher Full Text
27. Eftimovska-Otovic N, Grozdanovski R, Taneva B, et al.: Clinical characteristics of patients with intradialytic hypertension. Pril (Makedon Akad Nauk Umet Odd Med Nauki). 2015; 36(2): 187–193. PubMed Abstract | Publisher Full Text
28. Santos SF, Peixoto AJ, Perazella MA: How should we manage adverse intradialytic blood pressure changes? Adv. Chronic Kidney Dis. 2012 May; 19(3): 158–165. Publisher Full Text
29. Uduagbamen PK, Kadiri S: Intradialysis hypotension and hypertension in patients with end stage kidney disease in Nigeria: risk factors and clinical correlates. Ghana Med. J. 2021 Mar 31; 55(1): 34–42. PubMed Abstract | Publisher Full Text | Free Full Text
30. Zachariah S, Jagdale R, Sherief M: BP in Hemodialysis patients.xlsx. [Dataset]. figshare. 2023. Publisher Full Text

Comments on this article Comments (0)

Version 2

VERSION 2 PUBLISHED 14 Jun 2024

Author details Author details

Rajaram Jagdale
Roles: Conceptualization, Writing – Review & Editing

Competing interests

No competing interests were disclosed.

Grant information

The author(s) declared that no grants were involved in supporting this work.

Article Versions (2)

version 2

Revised

Published: 06 Jan 2025, 13:634

https://doi.org/10.12688/f1000research.144153.2

version 1

Published: 14 Jun 2024, 13:634

https://doi.org/10.12688/f1000research.144153.1

© 2025 Sherif M et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download

Export To

metrics

	Views	Downloads
F1000Research	-	-
PubMed Central Data from PMC are received and updated monthly.	-	-

Citations

SEE MORE DETAILS

CITE

how to cite this article

Sherif M, Zachariah S and Jagdale R. Association of intradialytic hypertension and antihypertensive medication use in patients undergoing maintenance hemodialysis: a prospective observational study [version 2; peer review: 1 approved with reservations, 1 not approved]. F1000Research 2025, 13:634 (https://doi.org/10.12688/f1000research.144153.2)

NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article.

track

receive updates on this article

Track an article to receive email alerts on any updates to this article.

Open Peer Review

Version 1

VERSION 1

PUBLISHED 14 Jun 2024

Views

Reviewer Report 01 Aug 2024

Peter K Uduagbamen, Bowen University / Bowen University Teaching Hospital, Ogbomosho, Nigeria

Approved with Reservations

https://doi.org/10.5256/f1000research.157907.r302267

Authors should mention specific timings for BP measurements. How were the necessary precautions in BP measurement effected?
What about the dialyzable and the non-dialyzable anti-hypertensive drugs and their effects.
Food taken within 30 minutes to an hour prior to dialysis and during dialysis could affect the intradialytic BP pattern, how was this taken care of?
A relationship between the hematocrit and the BP variation should also be given as lower values increases the risk of intradialytic hypotension.
Intradialytic hypotension commonly occur within the first 2 hours of dialysis while intradialytic hypertension common occur in the later part of dialysis, how was these fathom in the participants' preparation?
Again the gradient between pre and intra dialytic solute concentration also determine the intradialytic BP variations. So an assessment of the pre and post dialytic solute concentration would be very important.
Thiazides and diuretics particularly the thiazides are better drugs for managing systolic hypertension than other anti-hypertensives. It should have been kept in mind in participants preparation, data collection/analysis and finding a relationship between these drugs and cardiac output, end-diastolic volume and pressure, stroke volume and peripheral resistance.
These details are essential to strengthen this study.
Increase your references and cite recent studies on this topics. Intra dialytic blood pressure control appear more of a burden in Africa particularly sub-Sahara Africa, perhaps due to several prominent factors. Citing some authors from this region could only strengthen your study the more.
Please revise accordingly.

Is the work clearly and accurately presented and does it cite the current literature?

Partly
Is the study design appropriate and is the work technically sound?

Partly
Are sufficient details of methods and analysis provided to allow replication by others?

No
If applicable, is the statistical analysis and its interpretation appropriate?

Yes
Are all the source data underlying the results available to ensure full reproducibility?

No
Are the conclusions drawn adequately supported by the results?

No

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: nephrology, cardiology, metabolism, chemical pathology

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

CITE

Report a concern

Author Response 06 Jan 2025

Seeba Zachariah, College of Pharmacy, Gulf Medical University, Al Jurf, 4184, United Arab Emirates

06 Jan 2025

Author Response

1. Authors should mention specific timings for BP measurements. How were the necessary precautions in BP measurement effected?
Author Response: The dialysis center was functioning from 7 AM to 11 AM ... Continue reading 1. Authors should mention specific timings for BP measurements. How were the necessary precautions in BP measurement effected?
Author Response: The dialysis center was functioning from 7 AM to 11 AM and was working in 3 different shifts (morning, noon and evening). Most of the dialysis sessions were for 4 hours. Patients came at their scheduled timing for the dialysis.
Pre dialytic BP was measured before the start of dialysis, after 5 min rest period. Intradialytic BP was measured every 30 minutes, using an automatic cuff attached to the hemodialysis machine. All these BP measurements and data entry to the patient medical were done by the well-trained nurses in the center. The researcher calculated the average of 6 BP recording as the intradialytic BP. Precautions were taken to minimize the BP measurement effect by using validated BP monitors, trained nursing staff and by calculating the average of 6 periodic intradialytic BP readings.

2. What about the dialyzable and the non-dialyzable anti-hypertensive drugs and their effects?
Author Response: Details about dialyzability of antihypertensives and their effects are added in the introduction and results.

3.Food taken within 30 minutes to an hour prior to dialysis and during dialysis could affect the intradialytic BP pattern, how was this taken care of?
Author Response: Food taken with in 1 hour prior to hemodialysis or during dialysis can increase the risk of hypotension by increasing splenic and hepatic blood flow to the abdominal viscera and significantly reduces the venous return. All patients were educated by the dialysis team regarding dialysis procedure and instructions.

4. A relationship between the hematocrit and the BP variation should also be given as lower values increases the risk of intradialytic hypotension.
Author Response: This study checked relationship between anemia and BP variation. Hematocrit data was not used.

5. Again the gradient between pre and intra dialytic solute concentration also determine the intradialytic BP variations. So an assessment of the pre and post dialytic solute concentration would be very important.
Author Response: Even though using a low-sodium dialysate could reduce intradialytic hypertension events, all patients were given the same standard dialysate at the study site.

6. Thiazides and diuretics particularly the thiazides are better drugs for managing systolic hypertension than other anti-hypertensives. It should have been kept in mind in participants preparation, data collection/analysis and finding a relationship between these drugs and cardiac output, end-diastolic volume and pressure, stroke volume and peripheral resistance.
Author Response: These details are essential to strengthen this study. Increase your references and cite recent studies on this topics.
Thiazide diuretics were not used among the study population.

7. Intra dialytic blood pressure control appear more of a burden in Africa particularly sub-Sahara Africa, perhaps due to several prominent factors. Citing some authors from this region could only strengthen your study the more. Please revise accordingly.
Author Response: 2 citations are replaced with better ones.
1. Authors should mention specific timings for BP measurements. How were the necessary precautions in BP measurement effected?
Author Response: The dialysis center was functioning from 7 AM to 11 AM and was working in 3 different shifts (morning, noon and evening). Most of the dialysis sessions were for 4 hours. Patients came at their scheduled timing for the dialysis.
Pre dialytic BP was measured before the start of dialysis, after 5 min rest period. Intradialytic BP was measured every 30 minutes, using an automatic cuff attached to the hemodialysis machine. All these BP measurements and data entry to the patient medical were done by the well-trained nurses in the center. The researcher calculated the average of 6 BP recording as the intradialytic BP. Precautions were taken to minimize the BP measurement effect by using validated BP monitors, trained nursing staff and by calculating the average of 6 periodic intradialytic BP readings.

2. What about the dialyzable and the non-dialyzable anti-hypertensive drugs and their effects?
Author Response: Details about dialyzability of antihypertensives and their effects are added in the introduction and results.

3.Food taken within 30 minutes to an hour prior to dialysis and during dialysis could affect the intradialytic BP pattern, how was this taken care of?
Author Response: Food taken with in 1 hour prior to hemodialysis or during dialysis can increase the risk of hypotension by increasing splenic and hepatic blood flow to the abdominal viscera and significantly reduces the venous return. All patients were educated by the dialysis team regarding dialysis procedure and instructions.

4. A relationship between the hematocrit and the BP variation should also be given as lower values increases the risk of intradialytic hypotension.
Author Response: This study checked relationship between anemia and BP variation. Hematocrit data was not used.

5. Again the gradient between pre and intra dialytic solute concentration also determine the intradialytic BP variations. So an assessment of the pre and post dialytic solute concentration would be very important.
Author Response: Even though using a low-sodium dialysate could reduce intradialytic hypertension events, all patients were given the same standard dialysate at the study site.

6. Thiazides and diuretics particularly the thiazides are better drugs for managing systolic hypertension than other anti-hypertensives. It should have been kept in mind in participants preparation, data collection/analysis and finding a relationship between these drugs and cardiac output, end-diastolic volume and pressure, stroke volume and peripheral resistance.
Author Response: These details are essential to strengthen this study. Increase your references and cite recent studies on this topics.
Thiazide diuretics were not used among the study population.

7. Intra dialytic blood pressure control appear more of a burden in Africa particularly sub-Sahara Africa, perhaps due to several prominent factors. Citing some authors from this region could only strengthen your study the more. Please revise accordingly.
Author Response: 2 citations are replaced with better ones.
Competing Interests: No competing interests were disclosed. Close
Report a concern
Respond or Comment

COMMENTS ON THIS REPORT

Author Response 06 Jan 2025

Seeba Zachariah, College of Pharmacy, Gulf Medical University, Al Jurf, 4184, United Arab Emirates

06 Jan 2025

Author Response

1. Authors should mention specific timings for BP measurements. How were the necessary precautions in BP measurement effected?
Author Response: The dialysis center was functioning from 7 AM to 11 AM ... Continue reading 1. Authors should mention specific timings for BP measurements. How were the necessary precautions in BP measurement effected?
Author Response: The dialysis center was functioning from 7 AM to 11 AM and was working in 3 different shifts (morning, noon and evening). Most of the dialysis sessions were for 4 hours. Patients came at their scheduled timing for the dialysis.
Pre dialytic BP was measured before the start of dialysis, after 5 min rest period. Intradialytic BP was measured every 30 minutes, using an automatic cuff attached to the hemodialysis machine. All these BP measurements and data entry to the patient medical were done by the well-trained nurses in the center. The researcher calculated the average of 6 BP recording as the intradialytic BP. Precautions were taken to minimize the BP measurement effect by using validated BP monitors, trained nursing staff and by calculating the average of 6 periodic intradialytic BP readings.

2. What about the dialyzable and the non-dialyzable anti-hypertensive drugs and their effects?
Author Response: Details about dialyzability of antihypertensives and their effects are added in the introduction and results.

3.Food taken within 30 minutes to an hour prior to dialysis and during dialysis could affect the intradialytic BP pattern, how was this taken care of?
Author Response: Food taken with in 1 hour prior to hemodialysis or during dialysis can increase the risk of hypotension by increasing splenic and hepatic blood flow to the abdominal viscera and significantly reduces the venous return. All patients were educated by the dialysis team regarding dialysis procedure and instructions.

4. A relationship between the hematocrit and the BP variation should also be given as lower values increases the risk of intradialytic hypotension.
Author Response: This study checked relationship between anemia and BP variation. Hematocrit data was not used.

5. Again the gradient between pre and intra dialytic solute concentration also determine the intradialytic BP variations. So an assessment of the pre and post dialytic solute concentration would be very important.
Author Response: Even though using a low-sodium dialysate could reduce intradialytic hypertension events, all patients were given the same standard dialysate at the study site.

6. Thiazides and diuretics particularly the thiazides are better drugs for managing systolic hypertension than other anti-hypertensives. It should have been kept in mind in participants preparation, data collection/analysis and finding a relationship between these drugs and cardiac output, end-diastolic volume and pressure, stroke volume and peripheral resistance.
Author Response: These details are essential to strengthen this study. Increase your references and cite recent studies on this topics.
Thiazide diuretics were not used among the study population.

7. Intra dialytic blood pressure control appear more of a burden in Africa particularly sub-Sahara Africa, perhaps due to several prominent factors. Citing some authors from this region could only strengthen your study the more. Please revise accordingly.
Author Response: 2 citations are replaced with better ones.
1. Authors should mention specific timings for BP measurements. How were the necessary precautions in BP measurement effected?
Author Response: The dialysis center was functioning from 7 AM to 11 AM and was working in 3 different shifts (morning, noon and evening). Most of the dialysis sessions were for 4 hours. Patients came at their scheduled timing for the dialysis.
Pre dialytic BP was measured before the start of dialysis, after 5 min rest period. Intradialytic BP was measured every 30 minutes, using an automatic cuff attached to the hemodialysis machine. All these BP measurements and data entry to the patient medical were done by the well-trained nurses in the center. The researcher calculated the average of 6 BP recording as the intradialytic BP. Precautions were taken to minimize the BP measurement effect by using validated BP monitors, trained nursing staff and by calculating the average of 6 periodic intradialytic BP readings.

2. What about the dialyzable and the non-dialyzable anti-hypertensive drugs and their effects?
Author Response: Details about dialyzability of antihypertensives and their effects are added in the introduction and results.

3.Food taken within 30 minutes to an hour prior to dialysis and during dialysis could affect the intradialytic BP pattern, how was this taken care of?
Author Response: Food taken with in 1 hour prior to hemodialysis or during dialysis can increase the risk of hypotension by increasing splenic and hepatic blood flow to the abdominal viscera and significantly reduces the venous return. All patients were educated by the dialysis team regarding dialysis procedure and instructions.

4. A relationship between the hematocrit and the BP variation should also be given as lower values increases the risk of intradialytic hypotension.
Author Response: This study checked relationship between anemia and BP variation. Hematocrit data was not used.

5. Again the gradient between pre and intra dialytic solute concentration also determine the intradialytic BP variations. So an assessment of the pre and post dialytic solute concentration would be very important.
Author Response: Even though using a low-sodium dialysate could reduce intradialytic hypertension events, all patients were given the same standard dialysate at the study site.

6. Thiazides and diuretics particularly the thiazides are better drugs for managing systolic hypertension than other anti-hypertensives. It should have been kept in mind in participants preparation, data collection/analysis and finding a relationship between these drugs and cardiac output, end-diastolic volume and pressure, stroke volume and peripheral resistance.
Author Response: These details are essential to strengthen this study. Increase your references and cite recent studies on this topics.
Thiazide diuretics were not used among the study population.

7. Intra dialytic blood pressure control appear more of a burden in Africa particularly sub-Sahara Africa, perhaps due to several prominent factors. Citing some authors from this region could only strengthen your study the more. Please revise accordingly.
Author Response: 2 citations are replaced with better ones.
Competing Interests: No competing interests were disclosed. Close
Report a concern

Views

Reviewer Report 23 Jul 2024

Carmine Zoccali, Renal Research Institute, New York, New York, USA; Institute of Molecular Biology and Genetics (Biogem), Ariano Irpino, Italy; Associazione Ipertensione Nefrologia Trapianto Renale (IPNET), Reggio Calabria, Italy

Not Approved

https://doi.org/10.5256/f1000research.157907.r302273

The study aimed to assess intradialytic blood pressure (BP) complications and their association with various factors, including BP medication, in patients with end-stage kidney disease (ESKD) undergoing maintenance hemodialysis. It was a prospective observational study conducted at a hemodialysis center ... Continue reading

Small Sample Size: The study involved only 47 patients, which is a relatively small sample size. This limits the generalizability of the findings and increases the risk of type II errors.
Confounding Factors: The study is observational and thus inherently susceptible to confounding factors. The association between antihypertensive medications and intradialytic BP complications may be influenced by unmeasured variables such as patient comorbidities, dialysis parameters, and adherence to medication.
Contradictory Findings: The study's findings contrast with existing evidence from randomized clinical trials. For instance, small randomized trials have shown that amlodipine is well-tolerated and does not increase the risk of intradialytic hypotension, while beta-blockers are known to worsen hemodynamic tolerance to dialysis (Haddiya I, Valoti S: Current Knowledge of Beta-Blockers in Chronic Hemodialysis Patients. Int J Nephrol Renovasc Dis [Internet] Volume 16: 223–230, 2023).
Lack of Randomization: Without randomization, it is difficult to establish causality. The associations observed may not reflect true causal relationships.
Short Study Duration: The 6-month duration may not be sufficient to capture long-term trends and outcomes related to intradialytic BP complications.

While the study impacts a relevant clinical question, its small sample size and susceptibility to confounding limit the robustness of the conclusions. The findings contrast with existing evidence, particularly regarding the effects of beta-blockers and calcium channel blockers on hemodynamic tolerance during dialysis.

Is the work clearly and accurately presented and does it cite the current literature?

Partly
Is the study design appropriate and is the work technically sound?

No
Are sufficient details of methods and analysis provided to allow replication by others?

Yes
If applicable, is the statistical analysis and its interpretation appropriate?

No
Are all the source data underlying the results available to ensure full reproducibility?

No
Are the conclusions drawn adequately supported by the results?

Partly

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: hemodialysis, cardiovascular disease

I confirm that I have read this submission and believe that I have an appropriate level of expertise to state that I do not consider it to be of an acceptable scientific standard, for reasons outlined above.

CITE

Report a concern

Author Response 24 Jul 2024

Seeba Zachariah, College of Pharmacy, Gulf Medical University, Al Jurf, 4184, United Arab Emirates

24 Jul 2024

Author Response

Philosophical underpinning of this research is real-world observational, but the reviewer comments are from an experimental interventional research viewpoint. The mix up of research paradigms creates confusion. Causal relationship is ... Continue reading Philosophical underpinning of this research is real-world observational, but the reviewer comments are from an experimental interventional research viewpoint. The mix up of research paradigms creates confusion. Causal relationship is not a goal of our research, the research is to explore association of certain variables. As the study is a population-based no sampling was performed, no sample size was calculated, all eligible patient data were included. The findings are not for generalizing, but to encourage future research. Patient data for 6 months on BP having a few thousands of measurements provides a robust exploratory assessment, which is statistically valid. Confounding factors were also mentioned ignoring real-world research philosophy. All real-world research accommodates all factors that contribute and do not try to control the variables as in clinical trials. Even pragmatic clinical trials and intention-to-treat analysis are adopting real-world research philosophy elements. It is unfortunate compare all other research to per-protocol analysis type research strategy. Why not this real-world evidence contradicts to a ‘small’ clinical trial. The evidence generated from real-world research and clinical trial are to be interpreted differently or not. Duration of research is fair enough to explore association, may not be enough for finding causal relationship which is not an aim of this research.
Philosophical underpinning of this research is real-world observational, but the reviewer comments are from an experimental interventional research viewpoint. The mix up of research paradigms creates confusion. Causal relationship is not a goal of our research, the research is to explore association of certain variables. As the study is a population-based no sampling was performed, no sample size was calculated, all eligible patient data were included. The findings are not for generalizing, but to encourage future research. Patient data for 6 months on BP having a few thousands of measurements provides a robust exploratory assessment, which is statistically valid. Confounding factors were also mentioned ignoring real-world research philosophy. All real-world research accommodates all factors that contribute and do not try to control the variables as in clinical trials. Even pragmatic clinical trials and intention-to-treat analysis are adopting real-world research philosophy elements. It is unfortunate compare all other research to per-protocol analysis type research strategy. Why not this real-world evidence contradicts to a ‘small’ clinical trial. The evidence generated from real-world research and clinical trial are to be interpreted differently or not. Duration of research is fair enough to explore association, may not be enough for finding causal relationship which is not an aim of this research.
Competing Interests: No competing interests were disclosed. Close
Report a concern
Respond or Comment

COMMENTS ON THIS REPORT

Author Response 24 Jul 2024

Seeba Zachariah, College of Pharmacy, Gulf Medical University, Al Jurf, 4184, United Arab Emirates

24 Jul 2024

Author Response

Philosophical underpinning of this research is real-world observational, but the reviewer comments are from an experimental interventional research viewpoint. The mix up of research paradigms creates confusion. Causal relationship is ... Continue reading Philosophical underpinning of this research is real-world observational, but the reviewer comments are from an experimental interventional research viewpoint. The mix up of research paradigms creates confusion. Causal relationship is not a goal of our research, the research is to explore association of certain variables. As the study is a population-based no sampling was performed, no sample size was calculated, all eligible patient data were included. The findings are not for generalizing, but to encourage future research. Patient data for 6 months on BP having a few thousands of measurements provides a robust exploratory assessment, which is statistically valid. Confounding factors were also mentioned ignoring real-world research philosophy. All real-world research accommodates all factors that contribute and do not try to control the variables as in clinical trials. Even pragmatic clinical trials and intention-to-treat analysis are adopting real-world research philosophy elements. It is unfortunate compare all other research to per-protocol analysis type research strategy. Why not this real-world evidence contradicts to a ‘small’ clinical trial. The evidence generated from real-world research and clinical trial are to be interpreted differently or not. Duration of research is fair enough to explore association, may not be enough for finding causal relationship which is not an aim of this research.
Philosophical underpinning of this research is real-world observational, but the reviewer comments are from an experimental interventional research viewpoint. The mix up of research paradigms creates confusion. Causal relationship is not a goal of our research, the research is to explore association of certain variables. As the study is a population-based no sampling was performed, no sample size was calculated, all eligible patient data were included. The findings are not for generalizing, but to encourage future research. Patient data for 6 months on BP having a few thousands of measurements provides a robust exploratory assessment, which is statistically valid. Confounding factors were also mentioned ignoring real-world research philosophy. All real-world research accommodates all factors that contribute and do not try to control the variables as in clinical trials. Even pragmatic clinical trials and intention-to-treat analysis are adopting real-world research philosophy elements. It is unfortunate compare all other research to per-protocol analysis type research strategy. Why not this real-world evidence contradicts to a ‘small’ clinical trial. The evidence generated from real-world research and clinical trial are to be interpreted differently or not. Duration of research is fair enough to explore association, may not be enough for finding causal relationship which is not an aim of this research.
Competing Interests: No competing interests were disclosed. Close
Report a concern

Comments on this article Comments (0)

Version 2

VERSION 2 PUBLISHED 14 Jun 2024

Open Peer Review

Reviewer Status

Reviewer Reports

	Invited Reviewers
	1	2
Version 2 (revision) 06 Jan 25
Version 1 14 Jun 24	read	read

Carmine Zoccali, Renal Research Institute, New York, USA; Institute of Molecular Biology and Genetics (Biogem), Ariano Irpino, Italy; Associazione Ipertensione Nefrologia Trapianto Renale (IPNET), Reggio Calabria, Italy
Peter K Uduagbamen, Bowen University / Bowen University Teaching Hospital, Ogbomosho, Nigeria

Comments on this article

All Comments(0)

Add a comment

Browse by related subjects

Back to all reports

Reviewer Report

10 Views

01 Aug 2024 | for Version 1

Peter K Uduagbamen, Bowen University / Bowen University Teaching Hospital, Ogbomosho, Nigeria

10 Views Cite this report Responses(1)

Approved With Reservations

Is the work clearly and accurately presented and does it cite the current literature?

Partly
Is the study design appropriate and is the work technically sound?

Partly
Are sufficient details of methods and analysis provided to allow replication by others?

No
If applicable, is the statistical analysis and its interpretation appropriate?

Yes
Are all the source data underlying the results available to ensure full reproducibility?

No
Are the conclusions drawn adequately supported by the results?

No

Competing Interests

No competing interests were disclosed.

Reviewer Expertise

nephrology, cardiology, metabolism, chemical pathology

Respond to this report

Responses (1)

Author Response

06 Jan 2025

Seeba Zachariah, College of Pharmacy, Gulf Medical University, Al Jurf, 4184, United Arab Emirates

1. Authors should mention specific timings for BP measurements. How were the necessary precautions in BP measurement effected?
Author Response: The dialysis center was functioning from 7 AM to 11 AM and was working in 3 different shifts (morning, noon and evening). Most of the dialysis sessions were for 4 hours. Patients came at their scheduled timing for the dialysis.
Pre dialytic BP was measured before the start of dialysis, after 5 min rest period. Intradialytic BP was measured every 30 minutes, using an automatic cuff attached to the hemodialysis machine. All these BP measurements and data entry to the patient medical were done by the well-trained nurses in the center. The researcher calculated the average of 6 BP recording as the intradialytic BP. Precautions were taken to minimize the BP measurement effect by using validated BP monitors, trained nursing staff and by calculating the average of 6 periodic intradialytic BP readings.

2. What about the dialyzable and the non-dialyzable anti-hypertensive drugs and their effects?
Author Response: Details about dialyzability of antihypertensives and their effects are added in the introduction and results.

3.Food taken within 30 minutes to an hour prior to dialysis and during dialysis could affect the intradialytic BP pattern, how was this taken care of?
Author Response: Food taken with in 1 hour prior to hemodialysis or during dialysis can increase the risk of hypotension by increasing splenic and hepatic blood flow to the abdominal viscera and significantly reduces the venous return. All patients were educated by the dialysis team regarding dialysis procedure and instructions.

4. A relationship between the hematocrit and the BP variation should also be given as lower values increases the risk of intradialytic hypotension.
Author Response: This study checked relationship between anemia and BP variation. Hematocrit data was not used.

5. Again the gradient between pre and intra dialytic solute concentration also determine the intradialytic BP variations. So an assessment of the pre and post dialytic solute concentration would be very important.
Author Response: Even though using a low-sodium dialysate could reduce intradialytic hypertension events, all patients were given the same standard dialysate at the study site.

6. Thiazides and diuretics particularly the thiazides are better drugs for managing systolic hypertension than other anti-hypertensives. It should have been kept in mind in participants preparation, data collection/analysis and finding a relationship between these drugs and cardiac output, end-diastolic volume and pressure, stroke volume and peripheral resistance.
Author Response: These details are essential to strengthen this study. Increase your references and cite recent studies on this topics.
Thiazide diuretics were not used among the study population.

7. Intra dialytic blood pressure control appear more of a burden in Africa particularly sub-Sahara Africa, perhaps due to several prominent factors. Citing some authors from this region could only strengthen your study the more. Please revise accordingly.
Author Response: 2 citations are replaced with better ones.

View more View less

Competing Interests

No competing interests were disclosed.

Back to all reports

Reviewer Report

9 Views

23 Jul 2024 | for Version 1

9 Views Cite this report Responses(1)

Not Approved

Small Sample Size: The study involved only 47 patients, which is a relatively small sample size. This limits the generalizability of the findings and increases the risk of type II errors.
Confounding Factors: The study is observational and thus inherently susceptible to confounding factors. The association between antihypertensive medications and intradialytic BP complications may be influenced by unmeasured variables such as patient comorbidities, dialysis parameters, and adherence to medication.
Contradictory Findings: The study's findings contrast with existing evidence from randomized clinical trials. For instance, small randomized trials have shown that amlodipine is well-tolerated and does not increase the risk of intradialytic hypotension, while beta-blockers are known to worsen hemodynamic tolerance to dialysis (Haddiya I, Valoti S: Current Knowledge of Beta-Blockers in Chronic Hemodialysis Patients. Int J Nephrol Renovasc Dis [Internet] Volume 16: 223–230, 2023).
Lack of Randomization: Without randomization, it is difficult to establish causality. The associations observed may not reflect true causal relationships.
Short Study Duration: The 6-month duration may not be sufficient to capture long-term trends and outcomes related to intradialytic BP complications.

Is the work clearly and accurately presented and does it cite the current literature?

Partly
Is the study design appropriate and is the work technically sound?

No
Are sufficient details of methods and analysis provided to allow replication by others?

Yes
If applicable, is the statistical analysis and its interpretation appropriate?

No
Are all the source data underlying the results available to ensure full reproducibility?

No
Are the conclusions drawn adequately supported by the results?

Partly

Competing Interests

No competing interests were disclosed.

Reviewer Expertise

hemodialysis, cardiovascular disease

Respond to this report

Responses (1)

Author Response

24 Jul 2024

Seeba Zachariah, College of Pharmacy, Gulf Medical University, Al Jurf, 4184, United Arab Emirates

Philosophical underpinning of this research is real-world observational, but the reviewer comments are from an experimental interventional research viewpoint. The mix up of research paradigms creates confusion. Causal relationship is not a goal of our research, the research is to explore association of certain variables. As the study is a population-based no sampling was performed, no sample size was calculated, all eligible patient data were included. The findings are not for generalizing, but to encourage future research. Patient data for 6 months on BP having a few thousands of measurements provides a robust exploratory assessment, which is statistically valid. Confounding factors were also mentioned ignoring real-world research philosophy. All real-world research accommodates all factors that contribute and do not try to control the variables as in clinical trials. Even pragmatic clinical trials and intention-to-treat analysis are adopting real-world research philosophy elements. It is unfortunate compare all other research to per-protocol analysis type research strategy. Why not this real-world evidence contradicts to a ‘small’ clinical trial. The evidence generated from real-world research and clinical trial are to be interpreted differently or not. Duration of research is fair enough to explore association, may not be enough for finding causal relationship which is not an aim of this research.

View more View less

Competing Interests

No competing interests were disclosed.

Alongside their report, reviewers assign a status to the article:

Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested

Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.

Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions

[1] 1. Webster AC, Nagler EV, Morton RL, et al.: Chronic Kidney Disease. Lancet. 2017; 389(10075): 1238–1252. Publisher Full Text

[2] 2. Thurlow JS, Joshi M, Yan G, et al.: Global Epidemiology of End-Stage Kidney Disease and Disparities in Kidney Replacement Therapy. Am. J. Nephrol. 2021; 52(2): 98–107. PubMed Abstract | Publisher Full Text | Free Full Text

[3] 3. Al-Shamsi S, Regmi D, Govender RD: Chronic kidney disease in patients at high risk of cardiovascular disease in the United Arab Emirates: A population-based study. PLoS One. 2018; 13(6): e0199920. PubMed Abstract | Publisher Full Text | Free Full Text

[4] 4. Richards N, Hassan MH, Saleh AK, et al.: Epidemiology and referral patterns of patients with chronic kidney disease in the Emirate of Abu Dhabi. Saudi J. Kidney Dis. Transpl. 2015; 26(5): 1028–1034. PubMed Abstract | Publisher Full Text

[5] 5. O’Lone E, Viecelli AK, Craig JC, et al.: Cardiovascular Outcomes Reported in Hemodialysis Trials. J. Am. Coll. Cardiol. 2018; 71(24): 2802–2810. Publisher Full Text

[6] 6. Alzahrani AMA, al-Khattabi GH: Factors Influencing Adherence to Hemodialysis Sessions among Patients with End-Stage Renal Disease in Makkah City. Saudi J. Kidney Dis. Transpl. 2021; 32(3): 763–773. PubMed Abstract | Publisher Full Text

[7] 7. Sarafidis PA, Persu A, Agarwal R, et al.: Hypertension in dialysis patients: A consensus document by the European Renal and Cardiovascular Medicine (EURECA-M) working group of the European Renal Association–European Dialysis and Transplant Association (ERA-EDTA) and the hypertension and the Kidney Working Group of the European Society of Hypertension (ESH). Nephrol. Dial. Transplant. 2017; 32(4): 620–640. Publisher Full Text

[8] 8. Thomas D, Joseph J, Francis B, et al.: Effect of patient counseling on quality of life of hemodialysis patients in India. Pharm. Pract. 2009; 7(3): 181–184. PubMed Abstract | Publisher Full Text | Free Full Text

[9] 9. Kelly JT, Su G, Zhang L, et al.: Modifiable lifestyle factors for primary prevention of CKD: a systematic review and meta-analysis. J. Am. Soc. Nephrol. 2021; 32(1): 239–253. PubMed Abstract | Publisher Full Text | Free Full Text

[10] 10. Canaud B, Van der Sande F, Kooman J: Predialysis hyponatremia and positive change of natremia within hemodialysis sessions are strong indicators of poor cardiovascular outcome in hemodialysis patients. Kidney Int. Rep. 2021; 6(2): 248–251. PubMed Abstract | Publisher Full Text | Free Full Text

[11] 11. Agarwal R: Blood pressure and mortality among hemodialysis patients. Hypertension. 2010 Mar 1; 55(3): 762–768. PubMed Abstract | Publisher Full Text | Free Full Text

[12] 12. Burnier M, Damianaki A: Hypertension as cardiovascular risk factor in chronic kidney disease. Circ. Res. 2023 Apr 14; 132(8): 1050–1063. Publisher Full Text

[13] 13. Ahmed A, Jorna T, Bhandari S: Should we STOP angiotensin-converting enzyme inhibitors/angiotensin receptor blockers in advanced kidney disease? Nephron. 2016 Jun 24; 133(3): 147–158. PubMed Abstract | Publisher Full Text

[14] 14. Adejumo OA, Edeki IR, Oyedepo DS, et al.: The prevalence and risk of mortality associated with intradialytic hypertension among patients with end-stage kidney disease on haemodialysis: A systematic review and meta-analysis. PLoS One. 2024 Jun 11; 19(6): e0304633. PubMed Abstract | Publisher Full Text | Free Full Text

[15] 15. Tokareva A, Borovkova N, Polyakova I: High dialysis clearance of drugs predicts intradialytic hypertension in hemodialysis patients. Eur. Heart J. 2020 Nov 1; 41(Supplement_2): ehaa946.3325. Publisher Full Text

[16] 16. Bakris GL, Burkart JM, Weinhandl ED, et al.: Intensive Hemodialysis, Blood Pressure, and Antihypertensive Medication Use. Am. J. Kidney Dis. 2016 Nov 1; 68(5, Supplement 1): S15–S23. PubMed Abstract | Publisher Full Text Reference Source

[17] 17. Lefranc Torres A, Correa S, Mc Causland FR: Association of Calcium Channel Blocker Use With Intradialytic Hypotension in Maintenance Hemodialysis. Kidney Int. Rep. 2024 Mar 27; 9(6): 1758–1764. Publisher Full Text | PubMed Abstract | Free Full Text

[18] 18. Maruyama T, Takashima H, Abe M: Blood pressure targets and pharmacotherapy for hypertensive patients on hemodialysis. Expert Opin. Pharmacother. 2020 Jul 2; 21(10): 1219–1240. Publisher Full Text

[19] 19. Prasad B, Hemmett J, Suri R: Five Things to Know About Intradialytic Hypertension. Can. J. Kidney Health Dis. 2022 Jun 21; 9. PubMed Abstract | Publisher Full Text | Free Full Text

[20] 20. Canaud B, Chazot C, Koomans J, et al.: Fluid and hemodynamic management in hemodialysis patients: challenges and opportunities. J. Bras. Nefrol. 2019 October 24; 41: 550–559. PubMed Abstract | Publisher Full Text | Free Full Text

[21] 21. Flythe JE, Chang TI, Gallagher MP, et al.: Blood pressure and volume management in dialysis: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2020; 97(5): 861–876. PubMed Abstract | Publisher Full Text | Free Full Text

[22] 22. Fu EL, Clase CM, Evans M, et al.: Comparative Effectiveness of Renin-Angiotensin System Inhibitors and Calcium Channel Blockers in Individuals with Advanced CKD: A Nationwide Observational Cohort Study. Am. J. Kidney Dis. 2021; 77(5): 719–729.e1. PubMed Abstract | Publisher Full Text

[23] 23. Mujtaba F, Qureshi R, Dhrolia M, et al.: Frequency of Intradialytic Hypertension Using Kidney Disease: Improving Global Outcomes (KDIGO) Suggested Definition in a Single Hemodialysis Centre in Pakistan. Cureus. 2022 Dec 29; 14(12): e33104. PubMed Abstract | Publisher Full Text | Free Full Text

[24] 24. Hundemer GL, Knoll GA, Petrcich W, et al.: Kidney, Cardiac, and Safety Outcomes Associated with α-Blockers in Patients with CKD: A Population-Based Cohort Study. Am. J. Kidney Dis. 2021; 77(2): 178–189.e1. PubMed Abstract | Publisher Full Text

[25] 25. Inrig JK: Intradialytic hypertension: a less-recognized cardiovascular complication of hemodialysis. Am. J. Kidney Dis. 2010; 55(3): 580–589. PubMed Abstract | Publisher Full Text | Free Full Text

[26] 26. Locatelli F, Cavalli A, Tucci B: The growing problem of intradialytic hypertension. Nat. Rev. Nephrol. 2010 Jan; 6(1): 41–48. PubMed Abstract | Publisher Full Text

[27] 27. Eftimovska-Otovic N, Grozdanovski R, Taneva B, et al.: Clinical characteristics of patients with intradialytic hypertension. Pril (Makedon Akad Nauk Umet Odd Med Nauki). 2015; 36(2): 187–193. PubMed Abstract | Publisher Full Text

[28] 28. Santos SF, Peixoto AJ, Perazella MA: How should we manage adverse intradialytic blood pressure changes? Adv. Chronic Kidney Dis. 2012 May; 19(3): 158–165. Publisher Full Text

[29] 29. Uduagbamen PK, Kadiri S: Intradialysis hypotension and hypertension in patients with end stage kidney disease in Nigeria: risk factors and clinical correlates. Ghana Med. J. 2021 Mar 31; 55(1): 34–42. PubMed Abstract | Publisher Full Text | Free Full Text

[30] 30. Zachariah S, Jagdale R, Sherief M: BP in Hemodialysis patients.xlsx. [Dataset]. figshare. 2023. Publisher Full Text

Association of intradialytic hypertension and antihypertensive medication use in patients undergoing maintenance hemodialysis: a prospective observational study

Abstract

Background

Methods

Results

Conclusions

Keywords

Revised Amendments from Version 1

Introduction

Aim

Methods

Research design & setting

Study population

Ethical concerns

Data collection

Data analysis

Results

Table 1. Patient demographics at baseline.

Table 2. Average peri-dialytic values of 6 months study period (n=47).

Figure 1. Antihypertensive use among the study population (n=47).

Table 3. Association of antihypertensives to intradialytic Blood Pressure Complications.

Table 4. Effect of Antihypertensives on incidence of Intradialytic hypertension.

Discussion

Conclusion

Strengths and limitations

Data availability

References

Comments on this article Comments (0)

Open Peer Review

Comments on this article Comments (0)

Open Peer Review

Reviewer Status

Reviewer Reports

Comments on this article

Browse by related subjects

Competing Interests Policy

Stay Updated